Pekin Hardy Strauss Inc. Buys 59,640 Shares of uniQure N.V. $QURE

Key Points

• Pekin Hardy Strauss increased its uniQure stake by 63.3%, buying 59,640 shares in the third quarter to hold 153,890 shares, valued at about $3.7 million.
• The FDA granted priority review to uniQure’s AMT-130 application, with a target decision date of May 1, 2027; a planned confirmatory study of roughly 200 patients adds execution, cost, and clinical risks.
• uniQure’s latest quarterly loss narrowed to $0.88 per share, beating consensus, but revenue of $5.2 million fell short of estimates. Shares were reported down 8.8%.

Pekin Hardy Strauss Inc. raised its position in shares of uniQure N.V. (NASDAQ:QURE - Free Report) by 63.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 153,890 shares of the biotechnology company's stock after acquiring an additional 59,640 shares during the quarter. Pekin Hardy Strauss Inc. owned approximately 0.22% of uniQure worth $3,718,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Seven Fleet Capital Management LP bought a new position in shares of uniQure in the 2nd quarter worth approximately $15,254. IFP Advisors Inc boosted its position in shares of uniQure by 39.8% during the second quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company's stock valued at $128,000 after purchasing an additional 791 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of uniQure during the third quarter valued at approximately $86,000. Fulton Bank N.A. purchased a new stake in uniQure in the second quarter worth $220,000. Finally, Activest Wealth Management purchased a new stake in uniQure in the third quarter worth $121,000. Hedge funds and other institutional investors own 78.83% of the company's stock.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: The FDA granted priority review to uniQure’s BLA for AMT-130, with a target decision date of May 1, 2027. Acceptance and an expedited review provide a defined regulatory milestone for the company’s lead program. uniQure Q3 2026 results and company update
• Neutral Sentiment: Q3 loss narrowed year over year to $0.88 per share. That result beat some published consensus figures but missed another estimate; revenue of $5.2 million was below analyst expectations, leaving the quarter’s financial read-through mixed. UniQure Q3 loss narrows, revenue increases
• Negative Sentiment: The FDA review also puts the path beyond the application in focus: uniQure has outlined a confirmatory study of about 200 patients. The added study and its execution could mean further cost, time and clinical risk, tempering optimism around the 2027 decision date. AMT-130 confirmatory study and PDUFA date

uniQure Stock Down 8.8%

Shares of QURE opened at $21.01 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.52 and a quick ratio of 10.01. The business's 50 day moving average price is $32.42 and its 200-day moving average price is $29.68. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $51.72.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. The company had revenue of $5.20 million during the quarter, compared to analyst estimates of $6.17 million. uniQure had a negative return on equity of 96.34% and a negative net margin of 1,154.84%. On average, equities analysts predict that uniQure N.V. will post -3.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on QURE shares. Wall Street Zen downgraded uniQure from a "hold" rating to a "sell" rating in a report on Saturday, September 5th. Weiss Ratings upgraded shares of uniQure from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, September 21st. Barclays downgraded shares of uniQure from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $60.00 to $28.00 in a research report on Monday, October 5th. The Goldman Sachs Group decreased their price target on shares of uniQure from $46.00 to $31.00 and set a "neutral" rating for the company in a research note on Wednesday, September 30th. Finally, Stifel Nicolaus set a $71.00 price target on shares of uniQure in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $56.83.

uniQure Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure's best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure N.V. (NASDAQ:QURE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.